ENGOT-ov-6/TRINOVA-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer
European Journal of Cancer - United Kingdom
doi 10.1016/j.ejca.2016.09.004
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2017
Authors
Publisher
Elsevier BV